1. Scrip

Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi

 
• By Mandy Jackson

Entrectinib clinched double approvals in the US for ROS1-positive NSCLC and for tumors with NTRK gene fusions – making it the third tumor-agnostic and second NTRK-fusion approval in the US.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.
Rozlytrek will compete with Vitrakvi for NTRK gene fusion patients. • Source: Shutterstock

Roche's Genentech Inc. announced US Food and Drug Administration approval on 15 August for Rozlytrek (entrectinib) in two indications, making it the second drug approved in the US for solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion regardless of tumor type, behind Bayer AG's Vitrakvi (larotrectinib), which was cleared by the FDA last year.

Rozlytrek gained full approval to treat adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC) as well as accelerated approval...

More from New Products

More from Scrip

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

AI Is Inevitable, But Useful Only If Solves The Right Problems

 
• By Mandy Jackson

Scrip spoke with executives at artificial intelligence biotech firms and a big pharma company during the recent BIO conference about using AI in ways that add real value to drug development.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.